ArticleStroke2017
Atrial Fibrillation Genetic Risk and Ischemic Stroke Mechanisms.
Open access · bronzeAbstract read
In one paragraph
Article in Stroke, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Genotype-phenotype associations in atrial fibrillation: meta-analysis.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2019Pooled it
- Mechanistic Pathways Underlying Genetic Predisposition to Atrial Fibrillation Are Associated With Different Cardiac Phenotypes and Cardioembolic Stroke Risk.Circulation. Genomic and precision medicine · 2025Article
- Polygenic Risk and Cardiovascular Event Risk in Patients With Atrial Fibrillation With Low to Intermediate Stroke Risk.Journal of the American Heart Association · 2025Article
- Polygenic risk scores for atrial fibrillation and heart failure and the risk of stroke and dementia.Brain communications · 2025Article
- Predictive indicators in peripheral blood and left atrium blood for left atrial spontaneous echo contrast in atrial fibrillation patients.BMC cardiovascular disorders · 2024Article
- Clinical and Genetic Atrial Fibrillation Risk and Discrimination of Cardioembolic From Noncardioembolic Stroke.Stroke · 2023Article
- Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association.Circulation · 2023Review
- The Association Between Adult Height and Stroke Incidence in Japanese Men and Women: A Population-based Case-Control Study.Journal of epidemiology · 2023Article
- A nomogram to predict left atrial appendage thrombus and spontaneous echo contrast in non-valvular atrial fibrillation patients.BMC cardiovascular disorders · 2022Article
- Joint efficacy of the three biomarkers SNCA, GYPB and HBG1 for atrial fibrillation and stroke: Analysis via the support vector machine neural network.Journal of cellular and molecular medicine · 2022Article
- Atrial Fibrillation Genomics: Discovery and Translation.Current cardiology reports · 2021Review
- Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.Circulation · 2021Article
- Interactive Association Between CYP2C9 rs2860905 Polymorphism and Atrial Fibrillation on Ischemic Stroke in Taiwan Biobank Participants.Pharmacogenomics and personalized medicine · 2021Article
- Atrial fibrillation: villain or bystander in vascular brain injury.European heart journal supplements : journal of the European Society of Cardiology · 2020Article
- Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation.Circulation. Arrhythmia and electrophysiology · 2020Article
- Identification of Co-expressed Genes Between Atrial Fibrillation and Stroke.Frontiers in neurology · 2020Article
- The role of haematological traits in risk of ischaemic stroke and its subtypes.Brain : a journal of neurology · 2020Article
- Atrial fibrillation genetic risk differentiates cardioembolic stroke from other stroke subtypes.Neurology. Genetics · 2018Article
- Review
- Genetics of atrial fibrillation: an update.Current opinion in cardiology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 3 countries.
Steven A LubitzFrom the Stroke Research Center (C.D.A., J.R.), Center for Human Genetic Research (C.D.A., J.R.), and Cardiovascular Research Center (S.A.L., L.-C.W., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, The Broad Insitute of Harvard and MIT, Cambridge, MA (S.A.L., L.-C.W., C.D.A., J.R., P.T.E.); Autism Research Centre (O.E.P.) and Department of Clinical Neurosciences (H.S.M., M.T.), University of Cambridge, United Kingdom; Boston University and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (E.J.B.); Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians Universität, Germany (R.M., M.D.); Munich Cluster of Systems Neurology (SyNergy), Germany (M.D.); Division of Clinical Neurosciences, Neuroimaging Sciences and Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.S.); and Stroke Prevention Research Unit, Nuffield Department of Neuroscience, University of Oxford, United Kingdom (P.M.R.). slubitz@mgh.harvard.edu.
Owen E ParsonsFrom the Stroke Research Center (C.D.A., J.R.), Center for Human Genetic Research (C.D.A., J.R.), and Cardiovascular Research Center (S.A.L., L.-C.W., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, The Broad Insitute of Harvard and MIT, Cambridge, MA (S.A.L., L.-C.W., C.D.A., J.R., P.T.E.); Autism Research Centre (O.E.P.) and Department of Clinical Neurosciences (H.S.M., M.T.), University of Cambridge, United Kingdom; Boston University and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (E.J.B.); Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians Universität, Germany (R.M., M.D.); Munich Cluster of Systems Neurology (SyNergy), Germany (M.D.); Division of Clinical Neurosciences, Neuroimaging Sciences and Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.S.); and Stroke Prevention Research Unit, Nuffield Department of Neuroscience, University of Oxford, United Kingdom (P.M.R.).
Christopher D AndersonFrom the Stroke Research Center (C.D.A., J.R.), Center for Human Genetic Research (C.D.A., J.R.), and Cardiovascular Research Center (S.A.L., L.-C.W., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, The Broad Insitute of Harvard and MIT, Cambridge, MA (S.A.L., L.-C.W., C.D.A., J.R., P.T.E.); Autism Research Centre (O.E.P.) and Department of Clinical Neurosciences (H.S.M., M.T.), University of Cambridge, United Kingdom; Boston University and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (E.J.B.); Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians Universität, Germany (R.M., M.D.); Munich Cluster of Systems Neurology (SyNergy), Germany (M.D.); Division of Clinical Neurosciences, Neuroimaging Sciences and Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.S.); and Stroke Prevention Research Unit, Nuffield Department of Neuroscience, University of Oxford, United Kingdom (P.M.R.).
Emelia J BenjaminFrom the Stroke Research Center (C.D.A., J.R.), Center for Human Genetic Research (C.D.A., J.R.), and Cardiovascular Research Center (S.A.L., L.-C.W., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, The Broad Insitute of Harvard and MIT, Cambridge, MA (S.A.L., L.-C.W., C.D.A., J.R., P.T.E.); Autism Research Centre (O.E.P.) and Department of Clinical Neurosciences (H.S.M., M.T.), University of Cambridge, United Kingdom; Boston University and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (E.J.B.); Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians Universität, Germany (R.M., M.D.); Munich Cluster of Systems Neurology (SyNergy), Germany (M.D.); Division of Clinical Neurosciences, Neuroimaging Sciences and Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.S.); and Stroke Prevention Research Unit, Nuffield Department of Neuroscience, University of Oxford, United Kingdom (P.M.R.).
Rainer MalikFrom the Stroke Research Center (C.D.A., J.R.), Center for Human Genetic Research (C.D.A., J.R.), and Cardiovascular Research Center (S.A.L., L.-C.W., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, The Broad Insitute of Harvard and MIT, Cambridge, MA (S.A.L., L.-C.W., C.D.A., J.R., P.T.E.); Autism Research Centre (O.E.P.) and Department of Clinical Neurosciences (H.S.M., M.T.), University of Cambridge, United Kingdom; Boston University and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (E.J.B.); Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians Universität, Germany (R.M., M.D.); Munich Cluster of Systems Neurology (SyNergy), Germany (M.D.); Division of Clinical Neurosciences, Neuroimaging Sciences and Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.S.); and Stroke Prevention Research Unit, Nuffield Department of Neuroscience, University of Oxford, United Kingdom (P.M.R.).
Lu-Chen WengFrom the Stroke Research Center (C.D.A., J.R.), Center for Human Genetic Research (C.D.A., J.R.), and Cardiovascular Research Center (S.A.L., L.-C.W., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, The Broad Insitute of Harvard and MIT, Cambridge, MA (S.A.L., L.-C.W., C.D.A., J.R., P.T.E.); Autism Research Centre (O.E.P.) and Department of Clinical Neurosciences (H.S.M., M.T.), University of Cambridge, United Kingdom; Boston University and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (E.J.B.); Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians Universität, Germany (R.M., M.D.); Munich Cluster of Systems Neurology (SyNergy), Germany (M.D.); Division of Clinical Neurosciences, Neuroimaging Sciences and Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.S.); and Stroke Prevention Research Unit, Nuffield Department of Neuroscience, University of Oxford, United Kingdom (P.M.R.).
Martin DichgansFrom the Stroke Research Center (C.D.A., J.R.), Center for Human Genetic Research (C.D.A., J.R.), and Cardiovascular Research Center (S.A.L., L.-C.W., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, The Broad Insitute of Harvard and MIT, Cambridge, MA (S.A.L., L.-C.W., C.D.A., J.R., P.T.E.); Autism Research Centre (O.E.P.) and Department of Clinical Neurosciences (H.S.M., M.T.), University of Cambridge, United Kingdom; Boston University and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (E.J.B.); Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians Universität, Germany (R.M., M.D.); Munich Cluster of Systems Neurology (SyNergy), Germany (M.D.); Division of Clinical Neurosciences, Neuroimaging Sciences and Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.S.); and Stroke Prevention Research Unit, Nuffield Department of Neuroscience, University of Oxford, United Kingdom (P.M.R.).
Cathie L SudlowFrom the Stroke Research Center (C.D.A., J.R.), Center for Human Genetic Research (C.D.A., J.R.), and Cardiovascular Research Center (S.A.L., L.-C.W., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, The Broad Insitute of Harvard and MIT, Cambridge, MA (S.A.L., L.-C.W., C.D.A., J.R., P.T.E.); Autism Research Centre (O.E.P.) and Department of Clinical Neurosciences (H.S.M., M.T.), University of Cambridge, United Kingdom; Boston University and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (E.J.B.); Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians Universität, Germany (R.M., M.D.); Munich Cluster of Systems Neurology (SyNergy), Germany (M.D.); Division of Clinical Neurosciences, Neuroimaging Sciences and Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.S.); and Stroke Prevention Research Unit, Nuffield Department of Neuroscience, University of Oxford, United Kingdom (P.M.R.).
Peter M RothwellFrom the Stroke Research Center (C.D.A., J.R.), Center for Human Genetic Research (C.D.A., J.R.), and Cardiovascular Research Center (S.A.L., L.-C.W., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, The Broad Insitute of Harvard and MIT, Cambridge, MA (S.A.L., L.-C.W., C.D.A., J.R., P.T.E.); Autism Research Centre (O.E.P.) and Department of Clinical Neurosciences (H.S.M., M.T.), University of Cambridge, United Kingdom; Boston University and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (E.J.B.); Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians Universität, Germany (R.M., M.D.); Munich Cluster of Systems Neurology (SyNergy), Germany (M.D.); Division of Clinical Neurosciences, Neuroimaging Sciences and Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.S.); and Stroke Prevention Research Unit, Nuffield Department of Neuroscience, University of Oxford, United Kingdom (P.M.R.).
Jonathan RosandFrom the Stroke Research Center (C.D.A., J.R.), Center for Human Genetic Research (C.D.A., J.R.), and Cardiovascular Research Center (S.A.L., L.-C.W., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, The Broad Insitute of Harvard and MIT, Cambridge, MA (S.A.L., L.-C.W., C.D.A., J.R., P.T.E.); Autism Research Centre (O.E.P.) and Department of Clinical Neurosciences (H.S.M., M.T.), University of Cambridge, United Kingdom; Boston University and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (E.J.B.); Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians Universität, Germany (R.M., M.D.); Munich Cluster of Systems Neurology (SyNergy), Germany (M.D.); Division of Clinical Neurosciences, Neuroimaging Sciences and Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.S.); and Stroke Prevention Research Unit, Nuffield Department of Neuroscience, University of Oxford, United Kingdom (P.M.R.).
Patrick T EllinorFrom the Stroke Research Center (C.D.A., J.R.), Center for Human Genetic Research (C.D.A., J.R.), and Cardiovascular Research Center (S.A.L., L.-C.W., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, The Broad Insitute of Harvard and MIT, Cambridge, MA (S.A.L., L.-C.W., C.D.A., J.R., P.T.E.); Autism Research Centre (O.E.P.) and Department of Clinical Neurosciences (H.S.M., M.T.), University of Cambridge, United Kingdom; Boston University and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (E.J.B.); Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians Universität, Germany (R.M., M.D.); Munich Cluster of Systems Neurology (SyNergy), Germany (M.D.); Division of Clinical Neurosciences, Neuroimaging Sciences and Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.S.); and Stroke Prevention Research Unit, Nuffield Department of Neuroscience, University of Oxford, United Kingdom (P.M.R.).
Hugh S MarkusFrom the Stroke Research Center (C.D.A., J.R.), Center for Human Genetic Research (C.D.A., J.R.), and Cardiovascular Research Center (S.A.L., L.-C.W., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, The Broad Insitute of Harvard and MIT, Cambridge, MA (S.A.L., L.-C.W., C.D.A., J.R., P.T.E.); Autism Research Centre (O.E.P.) and Department of Clinical Neurosciences (H.S.M., M.T.), University of Cambridge, United Kingdom; Boston University and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (E.J.B.); Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians Universität, Germany (R.M., M.D.); Munich Cluster of Systems Neurology (SyNergy), Germany (M.D.); Division of Clinical Neurosciences, Neuroimaging Sciences and Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.S.); and Stroke Prevention Research Unit, Nuffield Department of Neuroscience, University of Oxford, United Kingdom (P.M.R.).
Matthew TraylorFrom the Stroke Research Center (C.D.A., J.R.), Center for Human Genetic Research (C.D.A., J.R.), and Cardiovascular Research Center (S.A.L., L.-C.W., P.T.E.), Massachusetts General Hospital, Boston; Program in Medical and Population Genetics, The Broad Insitute of Harvard and MIT, Cambridge, MA (S.A.L., L.-C.W., C.D.A., J.R., P.T.E.); Autism Research Centre (O.E.P.) and Department of Clinical Neurosciences (H.S.M., M.T.), University of Cambridge, United Kingdom; Boston University and National Heart, Lung and Blood Institute's Framingham Heart Study, MA (E.J.B.); Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, MA (E.J.B.); Department of Epidemiology, Boston University School of Public Health, MA (E.J.B.); Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians Universität, Germany (R.M., M.D.); Munich Cluster of Systems Neurology (SyNergy), Germany (M.D.); Division of Clinical Neurosciences, Neuroimaging Sciences and Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom (C.L.S.); and Stroke Prevention Research Unit, Nuffield Department of Neuroscience, University of Oxford, United Kingdom (P.M.R.).
WTCCC2, International Stroke Genetics Consortium, and AFGen Consortia
Massachusetts General Hospital · USCenter for Human Genetics · USFramingham Heart Study · USMunich Cluster for Systems Neurology · DEBoston University · USNational Heart Lung and Blood Institute · USUniversity of Edinburgh · GB
Funding
IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVALR01HL092577 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI BENJAMIN, EMELIA J., ELLINOR, PATRICK THOMAS · 2009 to 2025
$20.6MAFGen Consortium: Atrial Fibrillation Genomics to Functional AnalysesR01HL128914 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BENJAMIN, EMELIA J., ELLINOR, PATRICK THOMAS · 2015 to 2018
$3.1MMentoring in Arrhythmia ResearchK24HL105780 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI ELLINOR, PATRICK THOMAS · 2011 to 2020
$1.2MAtrial Fibrillation: Bridging genetic discovery and clinical associationsK23HL114724 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI LUBITZ, STEVEN A · 2013 to 2017
$893kBritish Heart Foundation RG/16/4/32218Doris Duke Charitable Foundation 2014105NHLBI NIH HHS K23 HL114724NHLBI NIH HHS K24 HL105780NHLBI NIH HHS R01 HL092577NHLBI NIH HHS R01 HL128914
Abstract
background and purposeAtrial fibrillation (AF) is a leading cause of cardioembolic stroke, but the relationship between AF and noncardioembolic stroke subtypes are unclear. Because AF may be unrecognized, and because AF has a substantial genetic basis, we assessed for predisposition to AF across ischemic stroke subtypes.
methodsWe examined associations between AF genetic risk and Trial of Org 10172 in Acute Stroke Treatment stroke subtypes in 2374 ambulatory individuals with ischemic stroke and 5175 without from the Wellcome Trust Case-Control Consortium 2 using logistic regression. We calculated AF genetic risk scores using single-nucleotide polymorphisms associated with AF in a previous independent analysis across a range of preselected significance thresholds.
resultsThere were 460 (19.4%) individuals with cardioembolic stroke, 498 (21.0%) with large vessel, 474 (20.0%) with small vessel, and 814 (32.3%) individuals with strokes of undetermined cause. Most AF genetic risk scores were associated with stroke, with the strongest association (
conclusionsComprehensive AF genetic risk scores were specific for cardioembolic stroke. Incomplete workups and subtype misclassification may have limited the power to detect associations with strokes of undetermined pathogenesis. Future studies are warranted to determine whether AF genetic risk is a useful biomarker to enhance clinical discrimination of stroke pathogeneses.
Indexed as
Genetic Association StudiesGenetic Predisposition to DiseaseAtrial FibrillationBrain IschemiaCase-Control StudiesEmbolismGenotypeHumansPolymorphism, Single NucleotideRisk FactorsStrokeUnited Kingdomatrial fibrillationgeneticsrisk factorssingle-nucleotide polymorphismstroke
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.